Clinical trials: Overweight and/or Obesity
Overweight , Obesity
Phase 2 Clinical Study of MWN105 Injection in Participants With Overweight or Obesity
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the pharmacokinetic characteristics, efficacy, and safety of MWN105 Injection in non-diabetic participants with overweight or obesity.
- Trial name
- NCT07804810
- Testing
- MWN105 1, MWN105 2, MWN105 3
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Obesity, Type 2 Diabetes
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight.
- Trial name
- NCT07564414
- Testing
- Cagrisema, Semaglutide
- Where
- 303 sites in United States, Argentina and 17 more
- Volunteers
- 2,500 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
A Study of LY3457263 in Obese Participants
The main purpose of this study is to evaluate the safety and tolerability of LY3457263 when administered in combination with tirzepatitide in overweight or obese participants.
- Trial name
- NCT05582096
- Testing
- LY3457263, Tirzepatide
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Volunteers (Diabetes Mellitus, Type 2)
A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.
NNC0519-0130 is a new medicine which may possibly help participants with type 2 diabetes, as it is expected to lower elevated sugar levels in the blood. The medicine may also lower the appetite.
- Trial name
- NCT05363774
- Testing
- NNC0519-0130
- Where
- 3 sites in Denmark, Germany
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Cardiovascular Disease, High Cardiovascular Risk
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with cardiovascular (CV) disease and/or multiple CV risk factors.
- Conditions
- Cardiovascular Disease, High Cardiovascular Risk, Obesity, Overweight
- Trial name
- CAMELLIA-TIMI (NCT02019264)
- Testing
- Lorcaserin hydrochloride
- Where
- 499 sites in United States, Australia and 6 more
- Volunteers
- 14,673 people
- Sponsor
- Eisai Inc.
Obesity &Amp; Overweight
Study to Evaluate the Efficacy and Safety of IN-B00009 Injection in Adults With Obesity or Overweight Without Diabetes Mellitus
This Phase 3 study is designed to evaluate the efficacy and safety of IN-B00009 injection in adults with obesity or overweight without diabetes mellitus
- Trial name
- NCT07192263
- Testing
- IN-B00009
- Volunteers
- 300 people
- Sponsor
- HK inno.N Corporation
Obesity, Overweight
A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight
This study in China is open to adults who are at least 18 years old who are living with overweight or obesity. People with a body mass index (BMI) of 28 kg/m^2 or higher or 24 kg/m^2 or higher with at least 1 weight related…
- Trial name
- NCT06214741
- Testing
- survodutide
- Where
- 28 sites in China
- Volunteers
- 307 people
- Sponsor
- Boehringer Ingelheim
Overweight or Obesity
A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE）
This is a multicenter, randomized, double-blind, placebo-controlled, phase III clinical study to evaluate the efficacy and safety of the oral small molecule MDR-001 Tablets over 52 weeks as an adjunct to a lifestyle intervention…
- Trial name
- NCT07274137
- Testing
- MDR-001
- Where
- 45 sites in China
- Volunteers
- 738 people
- Sponsor
- MindRank AI Ltd
Prediabetes, Type 2 Diabetes
Effect of Totum-63, Active Ingredient of Valedia, on Glucose and Lipid Homeostasis on Subjects With Prediabetes
Given the data on the active ingredients of Totum-63, this research aims to evaluate the effect of its chronic consumption (24 weeks) on glucose and lipid homeostasis and especially on fasting plasma glucose in volunteers with…
- Conditions
- Prediabetes, Type 2 Diabetes, Hypertriglyceridemia, Obesity
- Trial name
- TOTUM-63 TWO (NCT02868177)
- Testing
- Totum-63
- Where
- 6 sites in France, Ireland and 2 more
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Valbiotis
Obesity, Overweight and/or Obesity
A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity
The purpose of this study is to learn about the safety and effectiveness of berobenatide in adults with overweight or obesity who have already lost weight while taking semaglutide or tirzepatide.
- Conditions
- Obesity, Overweight and/or Obesity, Overweight, Treatment Of Obesity
- Trial name
- NCT07845500
- Testing
- Semaglutide, Berobenatide, Tirzepatide
- Where
- 26 sites in United States, Australia
- Volunteers
- 660 people
- Sponsor
- Pfizer
Obesity, Obstructive Sleep Apnea
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
This Phase 3 clinical trial is designed to evaluate the efficacy and safety of maridebart cafraglutide compared to placebo over a 52-week period in adults with obstructive sleep apnea (OSA) who are receiving positive airway…
- Trial name
- MARITIME-OSA-1 (NCT07225686)
- Testing
- Maridebart cafraglutide
- Where
- 61 sites in United States, Australia and 9 more
- Volunteers
- 250 people
- Sponsor
- Amgen
Safety, Healthy Subjects
A Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese Descent
This is a phase I, randomized, blinded study to evaluate the safety and pharmacokinetics of MEDI0382 following single dose administration to overweight/obese subjects of Japanese or Chinese descent
- Trial name
- NCT03385369
- Testing
- MEDI0382
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Metabolism and Nutrition Disorder, Obesity
Safety, Efficacy, Tolerability and Pharmacokinetics of NNC 0070-0002-0182 in Overweight or Obese Male and Female Volunteers
This trial will be conducted in the United States of America (USA). The aim of the trial is to investigate whether the drug is safe, well tolerated and to investigate the efficacy of NNC 0070-0002-0182 for the treatment of…
- Trial name
- NCT00665665
- Testing
- NNC 0070-0002-0182
- Where
- 2 sites in United States
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity, Genetic Obesity
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway
The protocol describes a randomized, double-blind, placebo-controlled trial with independent sub-studies of setmelanotide in patients with obesity and at least one of the specific gene variants in the Melanocortin-4 Receptor…
- Trial name
- NCT05093634
- Testing
- Setmelanotide
- Where
- 56 sites in United States, Canada and 8 more
- Volunteers
- 296 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Overweight, Obesity
A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight
This study is being done to find out how well a medicine called CagriSema helps people with overweight or obesity lose weight. CagriSema is still being tested in studies and is not yet available for doctors to prescribe.
- Trial name
- NCT07357766
- Testing
- Cagrisema
- Where
- 116 sites in United States, Bulgaria and 12 more
- Sponsor
- Novo Nordisk A/S
Adolescents With Obesity, Adolescents With Overweight & Weight-related Comorbidities
A Study of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents
The aim of the study is to evaluate the safety and efficacy of Ecnoglutide injection in overweight or obese Chinese adolescents
- Trial name
- NCT07836270
- Testing
- Ecnoglutide Injection
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.